[ad_1]
The new coronavirus vaccine developed by AstraZeneca and the University of Oxford is safe and triggers a similar immune system reaction in all adults, according to preliminary findings from a second-phase clinical trial.
The promising results of the second phase of the clinical trial were published Thursday in The Lancet, writes News.ro.
The study, which included 560 healthy adults, including 240 over the age of 70, found that the vaccine is safe and elicits a similar immune response in both people over 56 and over 70. 18-55 years.
Older people present “a significant risk“Developing severe forms of Covid-19, according to the World Health Organization (WHO), which cites lower immunity and possible chronic conditions. However, people of all ages are at risk of contracting the virus.
AstraZeneca, which collaborates with the University of Oxford, previously announced that interim data showed that the experimental vaccine elicits an immune system reaction in young adults and the elderly.
“It just came to our attention below. In this study we tried to analyze immune reactions in older adults and answer the question whether the immune system has a decreased ability to react as we age.“said Professor Andrew Pollard, head of Oxford’s vaccine clinical trials team.
Pollard also said that “These early data are really encouraging, they show that we get very good immune system reactions, even over 70 years, which seems similar to young adults.”
Reactions to vaccines
The candidate vaccine developed by Oxford causes very few side effects and has triggered reactions in parts of the immune system in all age groups, in low and standard doses.
Preliminary results showed that the vaccine, ChAdOx1 nCoV-19, triggered a T cell reaction within 14 days after the first dose and an antibody reaction within 28 days after the booster dose (revaccination).
The researchers hope that the T-cell reaction will play a role in long-term immunity to the virus.
Dr Maheshi Ramasamy, co-author of the Oxford University clinical trial, said that the reaction of antibodies and T cells in older adults is “Strong” and “encouraging”.
“Populations most at risk of developing a severe form of COVID-19 include people with pre-existing conditions and older adults. We hope this means that our vaccine will help protect the most vulnerable people in society, but more research is needed before we can be sure. “Ramasamy said.
The study authors showed that their results may be encouraging if the observed immune reactions are associated with protection against Covid-19 infections.
The second phase clinical trial did not evaluate the efficacy of the vaccine and a third phase clinical trial is underway to confirm this.
Results are expected this year, depending on the infection rate in the communities where the clinical trial is being conducted.
The authors mentioned some limitations of the second phase clinical trial, including the fact that participants in the elderly group are between 73 and 74 years old, have few chronic conditions, and the majority are white and non-smokers. The study of the third phase included people of various origins, countries and ethnicities.
Encouraging announcements from Pfizer and Moderna
Pfizer and BioNTech announced Wednesday, after a final analysis, that their Cobvid-19 vaccine is 95% effective in preventing infections.
Likewise, the biotechnology company Moderna announced earlier this week that, according to the preliminary results of its third-phase clinical study, its vaccine for the new coronavirus is 94.5% effective.
In Instagram ProTV News Find the images of the moment in the world!
CLICK HERE to install the FREE ProTV News App for Android Phones and iPhones!
[ad_2]
